''PLPL - otherwise known as Plandai or Plandai Biotechnology BECAME THE MAJORITY OWNER of TXTM"[/b]<<<<<<<<<<-----------
THIS IS MIND BLOWING!!! NO WAY THIS SHOULD BE TRADING IN THESE SUB-PENNY LEVELS!!!! THIS EXPLAINS THE 95 MILLION DOLLARE BUY. DOES WALLSTREET EVEN KNOW WHAT IS GOING ON HERE? CAN SOMEONE TEXT THEM OR EMAIL THEM THIS!!!! WE ARE SEVERELY UNDERVALUED!!!!
"Quote:
LETS BETTER UNDERSTAND THEN WHY THIS DEAL IS MUCH BIGGER THAN WE REALIZED:
IMO, In order to do this, we need to take a closer look at PLPL and what they have been doing the past 3 years IN PREPARATION for the 2/1/17 legalization of Medical MJ in South Africa.
2014 is a very monumental year in understanding the signifncance here:
PLPL - Plandai Biotechnology, Inc established its subsidiary Plandai SA, in 2014, to provide a platform for expanding the research of Plandaí's proprietary Phytofare® extracts into pharmaceutical application and then obtaining product claims.
FROM 2014-2015 NEWS :
Plandaí SA has the exclusive license and rights to develop, manufacture, and sell all current and future Phytofare® extracts for the pharmaceutical market worldwide. The first targeted product will focus on treating diabetes by regulating blood sugar levels with an expectation of being market ready by the latter half of 2017.
Plandaí SA will operate with distinct management concentrating on pharmaceutical applications and obtaining drug and structure-function claims
Plandaí SA will produce a finished product targeting a specific application, such as managing glucose levels in diabetics."
NOW THIS IS WHERE IT GETS VERY EXCITING IMO :
CHECK THIS OUT:
IN 2014- PLPL also created this subsidiary CANNABIS BIOSCIENCES,INC
PLPL, The Company, is actively pursuing research on additional botanical extracts that have known or suspected pharmaceutical properties. This research includes developing a non-psychoactive cannabinoid extract through the Company’s wholly-owned subsidiary, Cannabis Biosciences, Inc. This company has concluded its investigative research on cannabis and developed a method of extraction which it believes can produce a complete cannabis complex in a highly bioavailable format but without psychoactive effects. The Company obtained a license in Uruguay that will permit it to produce its cannabinoid extract and conduct laboratory research on live cannabis plant. Provided that the company can produce such an extract, the plan is to commence animal research on neural disorders such as Parkinson’s, Alzheimer’s, MS, epilepsy, and post-concussion syndrome in order to determine definitively if cannabis possesses medicinal properties meriting further human trials.''...
